Key result
Ticagrelor-aspirin cuts 90-day recurrent stroke ~23% vs clopidogrel-aspirin in minor stroke or TIA.
Why the study?
The efficacy and safety of different antiplatelet regimens in minor strokes or transient ischemic attacks remain controversial.
Does ticagrelor or dipyridamole plus aspirin improve efficacy and safety outcomes compared to other antiplatelet regimens in patients with minor stroke or TIA?
Meta-Analysis (n=61,281)
Does ticagrelor or dipyridamole plus aspirin improve efficacy and safety outcomes compared to other antiplatelet regimens in patients with minor stroke or TIA?
In patients with minor stroke or TIA, ticagrelor plus aspirin is more effective than clopidogrel plus aspirin for preventing recurrent events but carries a higher bleeding risk.
Answers are grounded in this paper and cite their sources.
Supports ticagrelor-aspirin over clopidogrel-aspirin for recurrent stroke prevention in minor stroke/TIA; challenges weak consensus while bleeding risk requires evaluation.
Background: The efficacy and safety of different antiplatelet in minor strokes or transient ischemic attacks (TIAs) remains controversial. Methods: We searched PubMed, Embase, Web of Science and the Cochrane Library to identify all eligible articles until 12 September 2024. Efficacy outcomes were all-cause mortality, excellent outcome, functional independence and recurrent stroke. Safety outcomes were any types of bleeding and intracerebral hemorrhage (ICH). The associations were calculated for the overall data by using the odds ratios (ORs). Results: 12 high-quality studies with 10 RCTs and 2 Non-RCTs were included, involving 61,281 patients with minor strokes or TIAs. Ticagrelor + Aspirin was significantly more effective than Clopidogrel + Aspirin in preventing post-stroke neurological dysfunctions (mRS 0-1), recurrent stroke and major vascular events for up to 90 days. But Ticagrelor + Aspirin is associated with an increased risk of any bleeding and mild bleeding at 90 days, and there is no significant difference in other bleeding risks. The risk of any bleeding in Dipyridamole + Aspirin is not significantly different from that in Aspirin, and is even significantly lower than in Ticagrelor. Compared with other dual antiplatelet therapies (DAPTs), Dipyridamole + Aspirin had no significant difference in the risk of all-cause mortality and major vascular events during follow-up. Conclusion: For minor strokes or TIAs with a low bleeding risk or CYP2C19 loss-of-function alleles, Ticagrelor + Aspirin may be a better choice than Clopidogrel + Aspirin. Due to limited studies, the superiority of Dipyridamole + Aspirin is still difficult to conclude, and further high-quality studies are needed to verify the benefits of Dipyridamole + Aspirin in minor stroke or TIAs. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42024537462.
No takes yet. Share an insight, caveat, or question.
Qin et al. (2025) conducted a meta-analysis in Minor stroke or transient ischemic attack (TIA) (n=61,281). Ticagrelor plus Aspirin vs. Clopidogrel plus Aspirin was evaluated on Recurrent stroke at 90 days (OR 0.77, 95% CI 0.63-0.92). Ticagrelor plus aspirin reduced the risk of recurrent stroke at 90 days compared to clopidogrel plus aspirin in patients with minor stroke or transient ischemic attack.
Synapse has enriched 10 related papers. Consider them for comparative context: